M L Montes
Overview
Explore the profile of M L Montes including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Montes M, Errico L, Mercader R, Taylor M
Chemosphere
. 2024 Aug;
364:143201.
PMID: 39214408
The activity of natural radionuclides is unevenly distributed across the Earth's crust, with certain areas exhibiting significantly higher levels than others, known as High Background Radiation Areas (HBRAs). This study...
2.
Busca-Arenzana C, Ortega-Gonzalez D, Diaz-Almiron M, Montes M, Martin-Carbonero L, Mican R, et al.
HIV Med
. 2024 May;
25(9):1030-1039.
PMID: 38746980
Background: Studies on switching to tenofovir alafenamide (TAF)-based regimens raise concerns about a worse metabolic profile in people with HIV, even though most received tenofovir disoproxil fumarate (TDF) in their...
3.
Palmier E, De Miguel R, Montejano R, Busca C, Mican R, Ramos L, et al.
HIV Med
. 2023 May;
24(9):1013-1019.
PMID: 37194419
Background: Dolutegravir (DTG) plus lamivudine (3TC) has proven highly efficacious as a switching strategy in virologically suppressed people with HIV (PWH). As this strategy was introduced relatively recently, real-world, long-term...
4.
Palacios R, Gomez-Ayerbe C, Casado J, Tejerina F, Montes M, Castano M, et al.
HIV Med
. 2023 Apr;
24(8):933-937.
PMID: 37016556
Introduction: Dolutegravir/rilpivirine (DTG/RPV) is an effective antiretroviral (ART) regimen endorsed by clinical trials as a switch therapy. The aim of our study was to analyse the efficacy and safety of...
5.
Busca C, Arias P, Sanchez-Conde M, Rico M, Montejano R, Martin-Carbonero L, et al.
Front Pharmacol
. 2022 Sep;
13:905126.
PMID: 36110512
Nonalcoholic fatty liver disease (NAFLD) is a common cause of liver damage in people living with HIV (PLWHIV). Several studies have investigated candidate genes for susceptibility to NAFLD and to...
6.
Busca C, Sanchez-Conde M, Rico M, Rosas M, Valencia E, Moreno A, et al.
Open Forum Infect Dis
. 2022 Jul;
9(7):ofac279.
PMID: 35873289
Background: Nonalcoholic fatty liver disease (NAFLD) is a major nonacquired immune deficiency syndrome-defining condition for persons with human immunodeficiency virus (PWH). We aimed to validate noninvasive tests for the diagnosis...
7.
Montes M, Rizzoto M, Ayub J, Torres Astorga R, Taylor M
J Environ Radioact
. 2019 Jul;
208-209:105998.
PMID: 31255900
Unsupported Pb (Pb) is generated in air and is subsequently deposited on soil surface. The Pb can be used for sediment dating, soil erosion/sedimentation and air mass studies. In many...
8.
Martin-Carbonero L, Montes M
Rev Clin Esp (Barc)
. 2019 May;
219(7):396-397.
PMID: 31076086
No abstract available.
9.
Olveira A, Dominguez L, Troya J, Arias A, Pulido F, Ryan P, et al.
J Viral Hepat
. 2018 Feb;
25(7):818-824.
PMID: 29476581
Guidelines recommend evaluating persistent alteration of liver tests in HCV-infected patients after sustained virological response (SVR) and its influence on liver disease progression. We studied the prevalence, etiology, associated factors...
10.
Laguno M, Von Wichmann M, van den Eynde E, Navarro J, Cifuentes C, Murillas J, et al.
Int J Infect Dis
. 2016 Nov;
53:46-51.
PMID: 27815225
Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC+pegylated interferon-α2a/ribavirin...